Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$33.72 - $47.33 $77,556 - $108,859
-2,300 Reduced 92.0%
200 $8,000
Q2 2024

Nov 01, 2024

BUY
$24.66 - $34.8 $56,718 - $80,040
2,300 Added 1150.0%
2,500 $86,000
Q2 2024

Aug 09, 2024

BUY
$24.66 - $34.8 $61,650 - $87,000
2,500 New
2,500 $86,000
Q2 2023

Aug 08, 2023

SELL
$18.02 - $29.36 $54,060 - $88,080
-3,000 Reduced 61.22%
1,900 $52,000
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $52,822 - $124,362
4,900 New
4,900 $112,000
Q2 2022

Jul 21, 2022

BUY
$7.06 - $25.52 $23,298 - $84,216
3,300 Added 1100.0%
3,600 $37,000
Q3 2021

Oct 19, 2021

BUY
$12.95 - $49.69 $3,885 - $14,907
300 New
300 $9,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.